News | September 11, 2024
Evonik starts operation of new spray drying facility for pharmaceutical oral excipients
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
The recent inspection covered both cGMP and PAI processes
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
Multi-year collaboration focuses on development of biodegradable antimicrobial peptides with broad application possibilities in the areas of skin care and healthcare
The Academy, led by Professor Ravi P Mahajan CBE, is set to harmonize the efforts of various Apollo entities
He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
Subscribe To Our Newsletter & Stay Updated
